

Appendix 1. Supplemental material

Search Strategy

1. Hip Fractures/
2. hip fracture*.mp. or intertrochanter* fracture*.mp. or femoral
3. neck fracture*.mp. or subtrochanter* fracture*.mp. or Bone
4. Nails/ or Arthroplasty, Replacement, Hip/ or Fracture Fixation/ or
5. Hemiarthroplasty/
6. exp Fracture Fixation, Intramedullary/ or exp Fracture Fixation,
7. Internal/
8. 1 or 2 or 3
9. exp Anticoagulants/
10. warfarin.mp. or warfarin.mp. or apixaban.mp. or rivaroxaban.
11. mp. or dabigatran.mp. or fondaparinux.mp. or edoxaban.mp or
12. Heparin/ or exp Aspirin/ or vitamin K antagonist.mp. or enoxaparin.
13. mp. or dalteparin.mp. or tinzaparin.mp. or nadroparin.mp.
14. 5 or 6
15. exp Venous Thromboembolism/ or exp Thromboembolism/ or
16. exp Embolism/ or exp Pulmonary Embolism/ or DVT.mp. or exp
17. Thrombosis/ or exp Venous Thrombosis/
18. exp Blood Loss, Surgical/ or exp Postoperative Hemorrhage/ or
19. exp Erythrocyte Transfusion/ or exp Blood Transfusion/ or exp
20. Blood Coagulation/
21. exp Patient Admission/ or exp Mortality/ or exp Survival Rate/
22. or exp Intraoperative Period/ or exp Time-to-Treatment/ or exp
23. Time Factors/
24. exp Patient Safety/ or exp Perioperative Care/ or exp
25. Cardiovascular Diseases/ or exp Risk Assessment/ or exp
26. Treatment Outcome/
27. 9 or 10 or 11
28. 4 and 7 and 12

DOI: 10.1503/cjs.010021

Online appendices are unedited and posted as supplied by the authors.

Supplemental Table S1. Quality assessment based on the Newcastle-Ottawa Scale of studies included in the systematic review.

Study	Selection			Outcome not present at start of study	Comparability*		Outcome		Total
	Representativeness of exposed cohort	Selection of non-exposed cohort	Ascertainment of exposure		Comparability of cohorts	Assessment of outcome	Length of follow-up	Adequacy of follow-up	
Buecking et al.	*	*	*	*		*	*	*	7
Moore et al.	*	*	*	*	*	*	*	*	8
Tal et al.	*	*	*	*		*	*	*	7
Shuetze et al.		*	*	*		*	*	*	7
Mattisson et al.	*	*	*	*	*	*	*	*	8
Ng et al.	*		*	*		*	*	*	6
Diament et al.	*	*	*	*		*	*	*	7
Ahmed et al.	*	*	*	*		*	*	*	6
Ashouri et al.	*	*	*	*			*	*	6
Vitale et al.	*	*	*	*	*	*	*	*	8
Bhatia et al.	*	*		*		*	*	*	6
Schermann et al.	*	*	*	*		*	*	*	7
Franklin et al	*			*	*	*	*	*	6
Mullins et al	*	*	*	*	*	*	*	*	8

*Two stars can be awarded to comparability of cohorts on the basis of design or analysis. All other categories can be awarded one star.